| The genetic landscape of high-risk neuroblastoma TJ Pugh, O Morozova, EF Attiyeh, S Asgharzadeh, JS Wei, D Auclair, ... Nature genetics 45 (3), 279-284, 2013 | 1258 | 2013 |
| Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study RH Ko, L Ji, P Barnette, B Bostrom, R Hutchinson, E Raetz, NL Seibel, ... Journal of clinical oncology 28 (4), 648-654, 2010 | 320 | 2010 |
| Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma S Asgharzadeh, JA Salo, L Ji, A Oberthuer, M Fischer, F Berthold, ... Journal of Clinical Oncology 30 (28), 3525-3532, 2012 | 307 | 2012 |
| Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B … PA Brown, L Ji, X Xu, M Devidas, LE Hogan, MJ Borowitz, EA Raetz, ... Jama 325 (9), 833-842, 2021 | 306 | 2021 |
| Outcome of children less than three years old at diagnosis with non‐metastatic medulloblastoma treated with chemotherapy on the “Head Start” I and II protocols G Dhall, H Grodman, L Ji, S Sands, S Gardner, IJ Dunkel, GB McCowage, ... Pediatric blood & cancer 50 (6), 1169-1175, 2008 | 259 | 2008 |
| Accuracy of predicting axillary lymph node positivity by physical examination, mammography, ultrasonography, and magnetic resonance imaging SA Valente, GM Levine, MJ Silverstein, JA Rayhanabad, ... Annals of surgical oncology 19, 1825-1830, 2012 | 242 | 2012 |
| Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group JA Van Doorninck, L Ji, B Schaub, H Shimada, MR Wing, MD Krailo, ... Journal of clinical oncology 28 (12), 1989-1994, 2010 | 189 | 2010 |
| Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed … J Fangusaro, J Finlay, R Sposto, L Ji, M Saly, S Zacharoulis, ... Pediatric blood & cancer 50 (2), 312-318, 2008 | 165 | 2008 |
| Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer H Jadvar, B Desai, L Ji, PS Conti, TB Dorff, SG Groshen, ME Gross, ... Clinical nuclear medicine 37 (7), 637-643, 2012 | 156 | 2012 |
| Critical role of STAT3 in IL-6–mediated drug resistance in human neuroblastoma T Ara, R Nakata, MA Sheard, H Shimada, R Buettner, SG Groshen, L Ji, ... Cancer research 73 (13), 3852-3864, 2013 | 151 | 2013 |
| Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer H Jadvar, B Desai, L Ji, PS Conti, TB Dorff, SG Groshen, JK Pinski, ... Journal of Nuclear Medicine 54 (8), 1195-1201, 2013 | 143 | 2013 |
| Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study MF Gorman, L Ji, RH Ko, P Barnette, B Bostrom, R Hutchinson, E Raetz, ... Pediatric blood & cancer 55 (3), 421-429, 2010 | 136 | 2010 |
| Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue S Zacharoulis, A Levy, SN Chi, S Gardner, M Rosenblum, DC Miller, ... Pediatric blood & cancer 49 (1), 34-40, 2007 | 132 | 2007 |
| Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide N Keshelava, E Davicioni, Z Wan, L Ji, R Sposto, TJ Triche, CP Reynolds Journal of the National Cancer Institute 99 (14), 1107-1119, 2007 | 118 | 2007 |
| Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature CY Yu, B Desai, L Ji, S Groshen, H Jadvar American journal of nuclear medicine and molecular imaging 4 (6), 580, 2014 | 110 | 2014 |
| Intensive induction chemotherapy followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for young children newly‐diagnosed with central … W Zaky, G Dhall, L Ji, K Haley, J Allen, M Atlas, S Bertolone, A Cornelius, ... Pediatric blood & cancer 61 (1), 95-101, 2014 | 107 | 2014 |
| Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children's Oncology Group Protocol AALL1621 MM O'Brien, L Ji, NN Shah, SR Rheingold, D Bhojwani, CM Yuan, X Xu, ... Journal of Clinical Oncology 40 (9), 956-967, 2022 | 100 | 2022 |
| A randomized phase 3 trial of blinatumomab vs. chemotherapy as post-reinduction therapy in high and intermediate risk (HR/IR) first relapse of B-acute lymphoblastic leukemia (B … PA Brown, L Ji, X Xu, M Devidas, L Hogan, MJ Borowitz, EA Raetz, ... Blood 134, LBA-1, 2019 | 96 | 2019 |
| A multi-institutional registry of pediatric hospital-acquired thrombosis cases: The Children's Hospital-Acquired Thrombosis (CHAT) project J Jaffray, A Mahajerin, G Young, N Goldenberg, L Ji, R Sposto, A Stillings, ... Thrombosis research 161, 67-72, 2018 | 87 | 2018 |
| Outcome of infants and young children with newly diagnosed ependymoma treated on the “Head Start” III prospective clinical trial R Venkatramani, L Ji, J Lasky, K Haley, A Judkins, S Zhou, R Sposto, ... Journal of neuro-oncology 113, 285-291, 2013 | 81 | 2013 |
